FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099108595> ?p ?o ?g. }

• W2099108595 endingPage "485" @default.
• W2099108595 startingPage "468" @default.
• W2099108595 abstract "A considerable interest in N-acetylcarnosine ocular drug design for eye health is based on clinical strategies to improve ocular drug delivery through metabolic enzymatic activation. Human biology aspects of ocular N-acetylcarnosine deacetylation during its pass through the cornea to the aqueous humor and dipeptide hydrolyzing enzymes are characterized. Novel approaches to ocular drug delivery increasing intraocular bioavailability of N-acetylcarnosine biologically activated metabolite carnosine become an integral development ensuring prolonged retention of the medication in the mucoadhesive precorneal area and facilitating transcorneal penetration of the natural dipeptide with the corneal promoters. A comprehensive list of techniques for peptide drug design, synthesis, purification, and biological analyses was considered: liquid chromatography (LC), high performance liquid chromatography (HPLC), (1) H and (13) C nuclear magnetic resonance (NMR), electrospray ionization (ESI) mass spectroscopy, and spectrophotometry. The antioxidant activity of therapeutics-targeted molecules was studied in aqueous solution and in a lipid membrane environment. A deglycation therapeutic system was developed involving removal, by transglycation of sugar or aldehyde moieties from Schiff bases by histidyl-hydrazide compounds or aldehyde scavenger L-carnosine. Clinical studies included ophthalmoscopy, visual acuity (VA), halometer disability glare tests, slit-image, and retro-illumination photography. N-acetylcarnosine 1% lubricant eye drops are considered as an auto-induction prodrug and natural ocular redox state balance therapies with implications in prevention and treatment of serious eye diseases that involve pathways of continuous oxidative damage to ocular tissues(cataracts, primary open-angle glaucoma, age-related macular degeneration) and sight-threatening glycosylation processes (diabetic retinopathy and consequent visual impairment) important for public health. The results of the study document that the therapeutic benefit in clinical trials is associated with the bioactivation universal antioxidant and transglycating properties of N-acetylcarnosine acting as the ophthalmic prodrug of L-carnosine, and depends on the nature of the specific drug delivery lubricant eye-drop formulation applied as the topical solution. The research highlights findings in N-acetylcarnosine prodrug activation, transport mechanisms, drug-to-drug interactions, and formulations in order to unlock the optimization of complicated ocular pharmacology of N-acetylcarnosine. Patented N-acetylcarnosine lubricant eye-drop formula was marketed as numerous human biological brands reaching important distribution networks on over 550 000 bottles sold. Nature Does Nothing Uselessly. -Aristotle" @default.
• W2099108595 created "2016-06-24" @default.
• W2099108595 creator A5027453092 @default.
• W2099108595 date "2011-03-18" @default.
• W2099108595 modified "2023-09-23" @default.
• W2099108595 title "Bioactivation antioxidant and transglycating properties of N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in mucoadhesive drug delivery eye-drop formulation: powerful eye health application technique and therapeutic platform" @default.
• W2099108595 cites W1538991079 @default.
• W2099108595 cites W1596694459 @default.
• W2099108595 cites W1969019110 @default.
• W2099108595 cites W1971443720 @default.
• W2099108595 cites W1972150645 @default.
• W2099108595 cites W1976820709 @default.
• W2099108595 cites W1976872447 @default.
• W2099108595 cites W1977895778 @default.
• W2099108595 cites W1979260208 @default.
• W2099108595 cites W1982350953 @default.
• W2099108595 cites W1983707612 @default.
• W2099108595 cites W1986029305 @default.
• W2099108595 cites W1994998336 @default.
• W2099108595 cites W1995086395 @default.
• W2099108595 cites W2002019037 @default.
• W2099108595 cites W2004430920 @default.
• W2099108595 cites W2005546891 @default.
• W2099108595 cites W2015497425 @default.
• W2099108595 cites W2015827383 @default.
• W2099108595 cites W2015970562 @default.
• W2099108595 cites W2017790981 @default.
• W2099108595 cites W2022619592 @default.
• W2099108595 cites W2032493697 @default.
• W2099108595 cites W2033420858 @default.
• W2099108595 cites W2033621140 @default.
• W2099108595 cites W2038558622 @default.
• W2099108595 cites W2040478432 @default.
• W2099108595 cites W2044289098 @default.
• W2099108595 cites W2048321718 @default.
• W2099108595 cites W2052184783 @default.
• W2099108595 cites W2055110785 @default.
• W2099108595 cites W2062285406 @default.
• W2099108595 cites W2064632591 @default.
• W2099108595 cites W2064925671 @default.
• W2099108595 cites W2066019537 @default.
• W2099108595 cites W2067758151 @default.
• W2099108595 cites W2070009772 @default.
• W2099108595 cites W2074201015 @default.
• W2099108595 cites W2075441556 @default.
• W2099108595 cites W2080971858 @default.
• W2099108595 cites W2082865005 @default.
• W2099108595 cites W2105366822 @default.
• W2099108595 cites W2122643622 @default.
• W2099108595 cites W2125379245 @default.
• W2099108595 cites W2128783891 @default.
• W2099108595 cites W2130439126 @default.
• W2099108595 cites W2136565033 @default.
• W2099108595 cites W2154647474 @default.
• W2099108595 cites W2164019365 @default.
• W2099108595 cites W2171528419 @default.
• W2099108595 cites W2172121372 @default.
• W2099108595 doi "https://doi.org/10.1002/dta.265" @default.
• W2099108595 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21416634" @default.
• W2099108595 hasPublicationYear "2011" @default.
• W2099108595 type Work @default.
• W2099108595 sameAs 2099108595 @default.
• W2099108595 citedByCount "5" @default.
• W2099108595 countsByYear W20991085952012 @default.
• W2099108595 countsByYear W20991085952013 @default.
• W2099108595 countsByYear W20991085952014 @default.
• W2099108595 crossrefType "journal-article" @default.
• W2099108595 hasAuthorship W2099108595A5027453092 @default.
• W2099108595 hasConcept C108215921 @default.
• W2099108595 hasConcept C178790620 @default.
• W2099108595 hasConcept C185592680 @default.
• W2099108595 hasConcept C2779820397 @default.
• W2099108595 hasConcept C2780687331 @default.
• W2099108595 hasConcept C55493867 @default.
• W2099108595 hasConcept C71924100 @default.
• W2099108595 hasConcept C98274493 @default.
• W2099108595 hasConceptScore W2099108595C108215921 @default.
• W2099108595 hasConceptScore W2099108595C178790620 @default.
• W2099108595 hasConceptScore W2099108595C185592680 @default.
• W2099108595 hasConceptScore W2099108595C2779820397 @default.
• W2099108595 hasConceptScore W2099108595C2780687331 @default.
• W2099108595 hasConceptScore W2099108595C55493867 @default.
• W2099108595 hasConceptScore W2099108595C71924100 @default.
• W2099108595 hasConceptScore W2099108595C98274493 @default.
• W2099108595 hasIssue "6" @default.
• W2099108595 hasLocation W20991085951 @default.
• W2099108595 hasLocation W20991085952 @default.
• W2099108595 hasOpenAccess W2099108595 @default.
• W2099108595 hasPrimaryLocation W20991085951 @default.
• W2099108595 hasRelatedWork W2012911400 @default.
• W2099108595 hasRelatedWork W2035824401 @default.
• W2099108595 hasRelatedWork W2077128780 @default.
• W2099108595 hasRelatedWork W2172224337 @default.
• W2099108595 hasRelatedWork W2559719377 @default.
• W2099108595 hasRelatedWork W2748952813 @default.
• W2099108595 hasRelatedWork W2899084033 @default.
• W2099108595 hasRelatedWork W2950130019 @default.
• W2099108595 hasRelatedWork W3133114354 @default.

• next